Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures

P. Vanherpe, S. Fieuws, A. D'Hondt, C. Bleyenheuft, P. Demaereel, J. De Bleecker, P. Van den Bergh, J. Baets, G. Remiche, K. Verhoeven, S. Delstanch, M. Toussaint, B. Buyse, P. Van Damme, C. E. Depuydt, and K. G. Claeys

Abstract

Background: Late-onset Pompe disease (LOPD) is a rare, hereditary, progressive disorder that is usually characterized by limb-girdle muscle weakness and/or respiratory insufficiency. LOPD is caused by mutations in the acid alpha-glucosidase (GAA) gene and treated with enzyme replacement therapy (ERT).

Methods: We studied the clinical, brain imaging, and genetic features of the Belgian cohort of late-onset Pompe disease patients (N = 52), and explored the sensitivity of different outcome measures, during a longitudinal period of 7 years (2010–2017), including the activity limitations ActivLim score, 6 min walking distance (6MWD), 10 m walk test (10MWT), MRC sum score, and forced vital capacity (FVC) sitting/supine.

Results: In Belgium, we calculated an LOPD prevalence of 3.9 per million. Mean age at onset of 52 LOPD patients was 28.9 years (SD: 15.8 y), ranging from 7 months to 68 years. Seventy-five percent (N = 39) of the patients initially presented with limb-girdle weakness, whereas in 13% (N = 7) respiratory symptoms were the only initial symptom. Non-invasive ventilation (NIV) was started in 37% (N = 19), at a mean age of 49.5 years (SD: 11.9 y), with a mean duration of 15 years (SD: 10.2 y) after symptom onset. Brain imaging revealed abnormalities in 25% (N = 8) of the patients, with the presence of small cerebral aneurysm(s) in two patients and a vertebrobasilar dolichoectasia in another two. Mean diagnostic delay was 12.9 years. All patients were compound heterozygotes with the most prevalent mutation being c.-32-13 T > G in 96%. We identified two novel mutations in GAA: c.1610_1611delA and c.186dup11. For the 6MWD, MRC sum score, FVC sitting and FVC supine, we measured a significant decrease over time (p = 0.0002, p = 0.0001, p = 0.0077, p = 0.0151), which was not revealed with the ActivLim score and 10MWT (p > 0.05).

Conclusions: Awareness on LOPD should even be further increased because of the long diagnostic delay. The 6MWD, but not the ActivLim score, is a sensitive outcome measure to follow up LOPD patients.

Keywords: Glycogen storage disease type 2, GSD2, Belgian cohort, ActivLim, 6MWD, Respiratory
Introduction

Pompe disease, also known as glycogen storage disease type 2 (GSD2) or acid maltase deficiency, is an autosomal recessive disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), resulting in the accumulation of glycogen in muscle cells. This usually leads to progressive limb-girdle muscle weakness and respiratory insufficiency, but heart, liver and the nervous system can also be affected [1–5]. Depending on the residual GAA enzyme activity, the disease either develops during the first months of life as the classic infantile Pompe disease (IOPD) [6], or later in life (childhood, adolescence or adulthood) with a milder phenotype known as late-onset Pompe disease (LOPD) [3]. Glycogen storage disease type 2 is a rare disorder, with an estimated prevalence of 1:283,000 in Europe [7]. Over 200 different mutations in the GAA gene have been described so far [8]. Current treatment consists of enzyme replacement therapy (ERT), which is reimbursed in Belgium since 2006 [9, 10], and supportive therapies such as (non-)invasive ventilation and physiotherapy. Similar to many other neuromuscular disorders, validated outcome measures are largely lacking in Pompe disease.

Here, we studied the clinical, brain imaging, and genetic features of the Belgian cohort of LOPD patients (N = 52), and the sensitivity of different outcome measures, during a longitudinal period of 7 years (2010–2017). One of the outcome measures was the activity limitations measure ActivLim [11–13], which has been evaluated previously in several other neuromuscular disorders, but not specifically in Pompe disease.

Patients and methods

LOPD patients

In this retrospective cohort study, we obtained pseudonymized data from LOPD patients from the seven neuromuscular reference centres in Belgium, where all the known LOPD patients are followed (N = 52), and from the Pompe disease registry (Sanofi-Genzyme). For patients receiving ERT in Belgium, a regular 6-month standardised follow-up and inclusion in a neuromuscular reference centre is mandatory. This allowed us to collect reliable data. We gathered the following patient data: gender, current age, age at onset, symptoms at onset, current disease stage, gene mutations, age at start of ERT, (non-)invasive ventilation and start-up age, serum creatine kinase (CK) (normal value for males < 190 U/l, females < 174 U/l), brain imaging either computed tomography (CT) including CT-angiography or magnetic resonance imaging (MRI) including MR-angiography. Furthermore, we studied the following functional data in the period between 2010 and 2017: forced vital capacity (FVC) in sitting and supine position (percentage of the predicted normal value), 6-min walk distance (6MWD), 10-m walk test (10MWT), Medical Research Council (MRC) sum score (shoulder abduction, elbow flexion, elbow extension, hip flexion, knee extension and knee flexion on both sides; each muscle group is scored between 0 and 5, maximum total score is 60), and the ActivLim (acronym of “ACTIVity LImitations”) questionnaire [11–13]. The latter comprises 22 daily activities to be rated by the patients as impossible, difficult or easy. It is a validated measure of daily activity limitations for patients with neuromuscular diseases [14]. A higher ActivLim score corresponds to a better functional level. The ActivLim score was computed using the Rasch model. Genetic analyses comprised both Sanger sequencing and MLPA analysis to also detect deletions and duplications. The genetic results were compared with the Pompe disease GAA variant database [8] and current literature [15].

Statistical analysis

We performed all statistical analyses using SAS software, version 9.4 of the SAS System for Windows. A linear mixed model with correlated random intercept and slope was used to evaluate the evolution of each variable as a function of the years since onset. Restricted cubic splines with four knots [16] were used to allow non-linearity. Likelihood-ratio tests were used to test the assumption of linearity, and to test if there was evidence for a change over time (in the model assuming linearity, as well as in the model allowing a nonlinear relation). The same methodology was used to verify the relation between the ActivLim score and each of the other variables. Thus, instead of using years since onset, the ActivLim score functioned as predictor in the model. After standardising the variables, the estimate of the slope in the model assuming linearity was reported. This estimate corresponds to a correlation coefficient. Note that this coefficient quantifies the association within a subject. To evaluate the cross-sectional correlation, which answers the question if a patient with on average high ActivLim values has also on average high values for another outcome measure, mean values per subject have been calculated and the correlation based on these mean values was reported.

Results

Prevalence of LOPD in Belgium

In Belgium, we identified 52 patients with LOPD, belonging to 48 families. The calculated prevalence of LOPD in Belgium is 3.9 per million, on a current population of 11,431,406 [7].

Demographic and clinical features of LOPD patients in the Belgian cohort (Table 1)

Twenty-seven patients were female (52%), 25 male (48%). Mean current age was 47.9 years (SD: 15.2 y; N =
| ID | Gender | Current age (y) | Current disease stage | Age at symptom onset (y) | Symptoms at onset | Duration of ERT (y) | Ventilation (age at startup in y) | Brain imaging | Year of genetic diagnosis (age in years) | GAA mutation 1 | GAA mutation 2 |
|----|--------|----------------|-----------------------|--------------------------|------------------|------------------|----------------------------------|---------------|--------------------------------------|---------------|---------------|
| 1  | F      | D (68y)        | D                     | 42                       | LW               | 2                | NIV (54y); invasive (68y)       | ND            | 2013 (65y)                           | c.-32-13 T > G | c.2219_2220del |
| 2  | F      | 66            | A                     | 58                       | R                | 4                | NIV (58y)                       | Normal (CT)   | 2014 (60y)                           | c.-32-13 T > G | c.2331 + 2 T > A |
| 3  | F      | 23            | A                     | 14                       | LW               | 8                | –                               | ND            | 2010 (14y)                           | c.-32-13 T > G | c.1564C > G |
| 4  | M      | 56            | A                     | 15                       | LW, F            | 13               | NIV (39y)                       | ND            | 2007 (44y)                           | c.-32-13 T > G | c.258dupC |
| 5  | M      | 55            | A                     | 26                       | LW, F            | 2                | NIV (53y)                       | ND            | 2016 (52y)                           | c.-32-13 T > G | c.2261dupC |
| 6  | F      | 65            | A                     | 13                       | LW               | 7                | –                               | ND            | 2012 (58y)                           | c.-32-13 T > G | c.258dupC |
| 7  | M      | 44            | A                     | 14                       | LW, F            | 4                | NIV (32y)                       | ND            | 2007 (32y)                           | c.-32-13 T > G | del exon 18 |
| 8  | M      | D (age?)      | D                     | 10                       | R                | 3                | invasive (42y)                   | ND            | 2007 (41y)                           | c.-32-13 T > G | c.956delT7 |
| 9  | F      | 75            | W                     | 49                       | LW               | 13               | –                               | Atrophy, mild microvascular white matter lesions (MRI) | 2005 (61y) | c.-32-13 T > G | c.525delT |
| 10 | M      | D (age?)      | D                     | 68                       | R                | 8                | NIV (75y)                       | ND            | NA                                   | c.-32-13 T > G | – |
| 11 | M      | 45            | A                     | 11                       | LW               | 13               | NIV (37y)                       | Normal (MRI)  | 2007 (33y)                           | c.-32-13 T > G | c.1548G > A |
| 12 | M      | 27            | A                     | 7                        | LW               | 14               | –                               | ND            | 2002 (20y)                           | c.-32-13 T > G | c.2331 + 2 T > A |
| 13a| F      | 45            | A                     | 36                       | LW               | 2                | –                               | ND            | NA                                   | c.-32-13 T > G | c.1115A > T |
| 14 a| M      | D (62y)      | D                     | NA                       | R                | 2                | NIV (58y)                       | ND            | 2005 (60y)                           | c.-32-13 T > G | – |
| 15a| M      | 55            | A                     | 30                       | R                | 13               | NIV(36y)                        | ND            | 2004 (40y)                           | c.-32-13 T > G | del exon 18 |
| 16a| M      | 59            | A                     | 52                       | NA               | 11               | –                               | Normal (MRI)  | 2004 (44y)                           | c.-32-13 T > G | del exon 18 |
| 17 | F      | 64            | A                     | 51                       | R, LW            | 9                | –                               | Normal (MRI)  | 2008 (53y)                           | c.-32-13 T > G | c.258dupC |
| 18 | F      | 27            | A                     | 11                       | NA               | 12               | –                               | Normal (MRI)  | 2006 (14y)                           | c.-32-13 T > G | c.258dupC |
| 19 | F      | 48            | A                     | 35                       | R, LW, AW        | 10               | –                               | Normal (MRI)  | 2008 (37y)                           | c.-32-13 T > G | del exon 18 |
| 20 | F      | 50            | A                     | 31                       | R, LW, AW        | 9                | –                               | Moderate ventriculomegaly (MRI) | 2009 (40y) | c.-32-13 T > G | c.692 + 1G > T |
| 21a| M      | 50            | A                     | 20                       | R, LW, AW        | 10               | –                               | Normal (MRI)  | 2008 (39y)                           | c.-32-13 T > G | c.1610_1611delA |
| 22a| M      | 47            | A                     | 37                       | R, LW, AW        | 9                | –                               | Normal (MRI)  | 2008 (36y)                           | c.-32-13 T > G | c.1610_1611delA |
| 23 | M      | 34            | A                     | 15                       | NA               | 7                | –                               | Normal (MRI)  | 2007 (22y)                           | c.-32-13 T > G | c.2608C > T |
| 24 | M      | 15            | A                     | 7 mo                     | NA               | 12               | –                               | Aspecific T2 hyperintensity in right thalamus (MRI) | 2007 (3y) | c.-32-13 T > G | del exon 18 |
| ID | Gender | Current age (y) | Current disease stage | Age at symptom onset (y) | Symptoms at onset | Duration of ERT (y) | Ventilation (age at startup in y) | Brain imaging | Year of genetic diagnosis (age in years) | GAA mutation 1 | GAA mutation 2 |
|----|--------|----------------|-----------------------|-------------------------|------------------|-------------------|-------------------------------|---------------|----------------------------------------|----------------|----------------|
| 25 | F      | 41             | A                     | 17                      | LW, R            | 8                 | –                             | Normal (MRI)  | 2007 (29y)                             | c.-32-13 T>G  | c.1655 T>C    |
| 26 | M      | 10             | A                     | 2.5                     | R, LW            | 6                 | –                             | Normal (MRI)  | 2013 (4y)                              | C2608C > T    | C.1839G > C   |
| 27 | F      | 59             | A                     | 43                      | R, LW, AW        | 5                 | –                             | Normal (MRI)  | 2013 (53y)                             | c.-32-13 T>G  | C.2608C > T   |
| 28 | F      | 35             | A                     | 28                      | R, LW, AW        | 3                 | –                             | Normal (MRI)  | 2015 (31y)                             | c.-32-13 T>G  | c.1121G > A   |
| 29 | F      | 23             | A                     | 9 mo                    | LW               | 14                | –                             | Normal (MRI)  | 2000 (4y)                              | c.-32-13 T>G  | c.923A > C    |
| 30 | M      | 63             | A                     | 39                      | R                | 13                | NIV (40 y)                   | Vertebrobasilar dolichoectasia, hypointensities in basal ganglia (SWI) (MRI) | 2007 (51y)   | c.-32-13 T>G  | c.258dupC     |
| 31 | F      | 50             | A                     | 35                      | LW               | 13                | –                             | Normal (MRI)  | 2007 (38y)                             | c.-32-13 T>G  | c.1548G > A   |
| 32 | F      | 73             | A                     | 28                      | LW               | 13                | –                             | ND            | 2007 (61y)                             | c.-32-13 T>G  | c.1710C > G   |
| 33 | F      | 63             | A                     | 44                      | LW               | 11                | –                             | Normal (CT)   | 2008 (52y)                             | c.-32-13 T>G  | c.1923G > A   |
| 34 | M      | 68             | A                     | 45                      | LW, ptosis left side | 12               | NIV (60 y)                   | Aneurysm right vertebral artery (MRI) | 2007 (66y)   | c.-32-13 T>G  | c.1681_1690dup19 |
| 35 | F      | D (78y)        | D                     | 44                      | LW, AW           | –                 | NIV (72 y)                   | Vascular leukoencephalopathy (CT) | 2007 (72y)   | c.-32-13 T>G  | c.1681_1690dup19 |
| 36 | M      | 47             | A                     | 25                      | LW               | 11                | –                             | Multiple small aneurysms (right ACI and left ACA) (MRI) | 2008 (36y)   | c.-32-13 T>G  | c.1075G > A   |
| 37 | M      | 45             | A                     | 17                      | LW               | 10                | –                             | Normal (MRI)  | 2009 (35y)                             | c.-32-13 T>G  | c.482_483del  |
| 38 | F      | 41             | A                     | 27                      | HyperCK, F       | 9                 | –                             | Normal (MRI)  | 2009 (31y)                             | c.-32-13 T>G  | c.525delT     |
| 39 | F      | 49             | A                     | 42                      | LW               | 7                 | –                             | Normal (MRI)  | 2011 (41y)                             | c.-32-13 T>G  | c.482_483delCC |
| 40 | F      | 35             | A                     | 18                      | LW               | 3                 | –                             | Normal (MRI)  | 2016 (32y)                             | c.-32-13 T>G  | c.2261dupC    |
| 41 | M      | 55             | A                     | 42                      | LW               | 2                 | NIV (53 y)                   | Normal (MRI)  | 2017 (53y)                             | c.-32-13 T>G  | c.2608C > T   |
| 42 | M      | 59             | A                     | 51                      | LW               | 5                 | –                             | ND            | 2014 (53y)                             | c.-32-13 T>G  | c.258dup     |
| 43 | F      | 63             | A                     | 25                      | LW               | 11                | –                             | ND            | 2011 (54y)                             | c.-32-13 T>G  | c.186dup11    |
| 44 | F      | 62             | A                     | 44                      | LW               | 7                 | –                             | ND            | 2007 (51y)                             | c.-32-13 T>G  | c.1115A > T   |
| 45 | F      | D (65y)        | D                     | 44                      | LW, R            | 7                 | NIV (55y)                   | Normal (CT)   | 2008 (57y)                             | c.-32-13 T>G  | c.701C > G    |
| 46 | M      | 58             | A                     | 27                      | LW               | 8                 | NIV (54y)                   | ND            | 2012 (51y)                             | c.-32-13 T>G  | c.258dup     |
| 47 | M      | 53             | A                     | 29                      | LW               | 11                | NIV (41y)                   | Normal (CT)   | 2008 (42y)                             | c.-32-13 T>G  | c.525delT    |
45), and mean age at symptom onset 28.9 years (range [7 mo – 68 y]; SD: 15.8 y). Two patients had onset of symptoms below 1 year of age (7 and 9 months); however, enzyme activity level and normal cardiac investigations were compatible with LOPD. In 75% of patients (N = 39), limb-girdle weakness was the initial symptom of the disease, presenting either as the only symptom or in combination with other abnormalities such as respiratory weakness and/or axial weakness and/or fatigue. One third (N = 17) of patients experienced respiratory problems as an initial symptom of the disease, and in 13% (N = 7) respiratory symptoms were the only initial symptom. In one patient, the disease presented with fatigue and an increased serum CK-level. Currently, only one of the 45 living patients is wheelchair-dependent, whereas the others are still ambulatory (although some of them use walking aids and/or a wheelchair for longer distances). Brain imaging (either CT of MRI) including imaging of the vessels was performed in 32 patients and revealed abnormalities in eight patients (25%). Small cerebral aneurysm(s) were detected in two patients and a vertebrobasilar dolichoectasia in another two (Table 1).

All patients were treated with enzyme replacement therapy (ERT), except one patient because of advanced age and severe clinical stage at the time of ERT introduction (patient 35, Table 1). Mean age at start-up of ERT was 41.2 years (SD: 15.9 y) and mean duration of ERT treatment up to now was 8.1 y (SD: 4.0 y). Nineteen patients (37%) were treated with non-invasive ventilation (NIV) starting at a mean age of 49.5 years (range [32–75], SD: 11.9 y), with a mean duration of 15 years (SD: 10.2 y) after symptom onset. One of these patients subsequently needed invasive ventilation at the age of 68 years, 14 years after starting NIV (patient 1, Table 1). Another patient was treated immediately with invasive ventilation at age 42 years, due to respiratory failure (patient 8, Table 1). Interestingly, this patient presented with respiratory difficulties as a first symptom at age 10 years. Mean serum-CK levels prior to ERT were 686 U/l (range [65–2246], SD: 510 U/l), whereas the current mean serum-CK values (under ERT) were 399 U/l (range [19–1303], SD: 326 U/l).

### Diagnosis and genetic results in LOPD patients in the Belgian cohort (Table 1)

In our cohort, all patients were compound heterozygotes, none of them carried homozygous mutations in GAA. The majority (49/51, 96%) harboured the frequent c.-32-13 T > G (IVS1) mutation in the GAA-gene. We identified a novel GAA mutation in three patients belonging to two different families: c.1610_1611delA (patients 21 and 22) and c.186dup11 (patient 43, Table 1). In two patients, we identified only one mutation in GAA, but we could not find a second mutation (patients 10 and 14, Table 1). However, the diagnosis in these patients was proven by reduced GAA enzymatic activity in blood and muscle tissue. Mean age at genetic diagnosis was 40.8 years (SD: 16.4 y), and diagnostic delay between symptom onset and genetic diagnosis 12.9 years (range [0–45], SD: 10.8 y).

### Data on motor performances (6MWD, 10MWT, MRC sum score), respiratory function (FVC) and ActivLim score in LOPD patients

The last measured mean value for 6MWD was 385.1 m (SD: 167.7), for 10MWT 9.2 s (SD: 6.9), for the MRC sum score 49.7 (SD: 6.7), FVC sitting 73.8% (SD: 25.7).
and FVC supine 57.3% (SD: 25.3). For the patients using (non-)invasive ventilation (N = 19), mean FVC sitting was 51.1% (SD: 24.8) and mean FVC supine 33.0% (SD: 15.5).

Longitudinal data on 6MWD, 10MWT, MRC sum score, FVC sitting, FVC supine and ActivLim score were available for 43, 41, 44, 48 and 33 out of 51 patients, respectively (Fig. 1). Most observations were made during the first 25 years after disease onset: 195/222 (88%) for 6MWD, 182/210 (87%) for 10MWT, 186/213 (87%) for MRC sum score, and for FVC sitting 219/253 (87%), FVC supine 159/186 (85%) and ActivLim score 126/151 (83%). For some of the outcome measures there seems to be an improvement initially, before deterioration becomes obvious. We calculated the evolution over time (years after symptom onset) for the different outcome measures (6MWD, 10MWT, MRC sum score, FVC sitting and supine, ActivLim score). For the 6MWD, MRC sum score, FVC sitting and FVC supine, we observed a significant decrease over time (p = 0.0002, p = 0.0001, p = 0.0077, p = 0.0151, respectively) (Fig. 2, Table 2). For the ActivLim score, we observed a non-significant linear decrease over time (p = 0.0938). Excluding one outlier, there was also no significant change for the 10MWT over time (p > 0.05) (Fig. 2, Table 2).

Correlation of longitudinal motor and respiratory outcome measures (6MWD, 10MWT, MRC sum score, FVC sitting, FVC supine) with the ActivLim score

Two correlations were performed: a cross-sectional correlation based on the mean values per subject (differences in number of measurements were ignored as simplification) and the within-subject correlation as derived from the mixed model. For the 6MWD, there is a significant correlation for the mean values per subject and the within-subject measurements (p = 0.0005, p = 0.0018, respectively). For the 10MWT, we also found significant correlations for these two measures (p = 0.0010, p = 0.0001, respectively), after exclusion of one outlier. For MRC sum score there was a significant correlation when comparing means per subject (p = 0.0240), but not within-subject (p > 0.05). For FVC values, both sitting and supine, there was a significant correlation when comparing means per subject (p = 0.0082, p = 0.0044, respectively), but within-subject only for supine FVC (p = 0.0346).

Discussion

LOPD is a rare disease and associated with a long diagnostic delay

We established a prevalence of LOPD in Belgium of 3.9 per million or 1:256,000. An overall estimated prevalence of 1:283,000 has been reported in Europe [17, 18]. A cohort study in Austria revealed an even lower prevalence of 1:351,000 of Pompe disease (including both LOPD and infantile forms) [18]. Thus, LOPD is a rare disease, and the low prevalence may be one explanation for the long diagnostic delay of almost 13 years in our study, 7.4 years in the Austrian cohort [18], about 5 years in a Chinese patient group [19] and 3.3 years in an Iranian cohort [20]. Furthermore, the clinical presentation is variable and can be mild and non-specific, especially at the beginning of the disease. Some patients are paucisymptomatic and only present with hyperCKemia or fatigue. Importantly, in 13% of our patients, respiratory symptoms were the only initial symptom of the disease. Early recognition and diagnosis of Pompe disease is important since treatment (ERT) is available and it has been shown that ERT is more efficient in early disease stages [9]. In later disease stages, patients with LOPD mainly show limb-girdle and axial muscle weakness with or without respiratory symptoms, which was also the case in our study population. In order to decrease the long diagnostic delay in LOPD patients, awareness on LOPD as a rare disease should be significantly raised further.

Cerebral (vascular) abnormalities in LOPD

Brain imaging (either CT or MRI) including imaging of the vessels revealed abnormalities in 25% (N = 8) of the patients. Most anomalies were nonspecific findings but in two patients small cerebral aneurysm(s) (2/32; 6.5%) were detected and a vertebrobasilar dolichoectasia in another two (2/32; 6.5%). Recent studies in LOPD showed a relative higher prevalence of intracranial abnormalities than we found in our study. Montagnese et al. [21] revealed the presence of aneurysms in 9.5% of LOPD patients (2/21) and a vertebrobasilar dolichoectasia in another two (2/21; 6.5%). Musumeci et al. [22] also reported a higher prevalence of intracranial aneurysms (3/21; 14%) and a vertebrobasilar dolichoectasia (11/21; 52%) in LOPD patients. Furthermore, in both studies a relatively high frequency of lacunar encephalopathy was reported (62 and 57%, respectively). Management guidelines for aneurysms and other intracranial abnormalities in Pompe disease are lacking; mostly, current general recommendations for surgery or for radiologic follow-up are used. As intracranial vascular anomalies can lead to serious complications, performing brain imaging (preferably MRI with MR angiography) in LOPD patients, at least once at the time of diagnosis, is recommended [23]. If aneurysms are detected and warrant no treatment, brain imaging should be repeated every 6–12 months, as indicated by the guidelines of the American Stroke Association for brain aneurysms in general [24].

The 6MWD, MRC sum score, FVC sitting and FVC supine are sensitive longitudinal outcome measures in LOPD, in contrast to the ActivLim score and 10MWT

Defining appropriate outcome measures is important to understand the disease course and to better design
current and future clinical trials in LOPD. We obtained longitudinal data on distinct outcome measures in our study population between 2010 and 2017, irrespective of age, clinical status, disease duration or therapy duration. We studied both motor and respiratory parameters. FVC is measured both in sitting and supine position, because diaphragmatic involvement, which frequently occurs in LOPD, can be measured by a significant difference of more than 25% between the two FVC values. For the 6MWD, MRC sum score, FVC sitting and FVC supine, we measured a significant decrease over time in LOPD patients, even though they were treated with ERT. This deterioration was not revealed by the 10MWT and ActivLim.
score, although our data suggested a trend towards a decline.

Vandervelde et al. [12] showed that in several other neuromuscular diseases, such as Duchenne muscular dystrophy, other muscular dystrophies and Charcot-Marie-Tooth neuropathy, the ActivLim score was possibly even more sensitive than patients’ self-perception to report change in functional status (overall better, stable or worse). In Batcho et al. [13], the ActivLim score (analysed with the rating scale Rasch model) was validated in a more heterogeneous group of neuromuscular disorders in the longitudinal monitoring of
of ERT and of ERT duration. Clinically, over the years, but we collected data irrespective of the start of ERT. Similarly, in our cohort, the 6MWD declined from 373.5 m \[18\], and Kuperus et al. \[30\] showed that the median 6MWD changed from 376 to 416 m over a period of 5 years following ERT onset. They measured a decrease in FVC in non-treated Pompe patients would possibly be felt after 2 years, for the 6MWD this would be 9 years. This might also be an explanation why there is a change in some outcome measures, but not in the ActivLim score.

Not all changes in outcome measurements in neuromuscular diseases result in a change in functionality \[26\], the relation between motor function and activity level is not necessarily straightforward \[27, 28\]. Declines in walking distance, speed or forced vital capacity are not necessarily clinically significant or even perceived as a decline by the patient. Therefore, activity limitations should be assessed separately in patients with neuromuscular diseases, but in LOPD patients the ActivLim score may not be the best patient reported outcome measure to assess this.

When comparing mean values of respiratory function and 6MWD, findings in our LOPD cohort are comparable to earlier described LOPD patient groups \[10, 18, 29, 30\]. In the Austrian cohort, 6MWD during ERT was 373.5 m \[18\], and Kuperus et al. \[30\] showed that the median 6MWD changed from 376 to 416 m over a period of 5 years following ERT onset. They measured an increase in 6MWD during the first year after treatment onset, and a decline from then on. In the meta-analysis of Schoser et al. \[10\], where distances between 246 and 660 m were measured, the largest improvement of the 6MWD was measured the first 20 months after start of ERT. Similarly, in our cohort, the 6MWD declined over the years, but we collected data irrespective of ERT and of ERT duration.

The 6-min walk distance (6MWD) is most commonly used to measure exercise capacity in LOPD \[26, 31\]. This capacity may be limited by multiple causes, such as peripheral muscle weakness and respiratory function. Furthermore, this may vary between patients. In Duchenne and Becker muscular dystrophy, as well as in some pulmonary diseases, the 6MWD is a validated outcome measure, often used in combination with other tests, such as quantitative muscle MRI and Motor Function Measure \[26\]. Similarly to previous longitudinal cohorts in neuromuscular diseases \[32\], we showed that the 6MWD was a good outcome parameter in LOPD.

**Table 2** Significance levels of outcome measures over time

| Outcome Measure | Nonlinearity | Evolution over time |
|-----------------|--------------|---------------------|
| ActivLim        | 0.9792       | 0.0938              |
| 6MWD            | 0.0062       | 0.0102              |
| 10MWT           | 0.1195       | 0.2676              |
| MRC sum         | 0.0431       | 0.0006              |
| FVC sitting     | 0.5594       | 0.0077              |
| FVC supine      | 0.7773       | 0.0151              |

*Results (p-values) likelihood-ratio tests from mixed models evaluating the evolution of each of the outcome measures as a function of years since onset. Nonlinearity: is there evidence that the relation is nonlinear (nonlinearity). Linear, nonlinear: is there evidence that the measure changes over time (assuming linearity, and allowing nonlinearity, respectively).*

functional status. However, these two studies did not include patients with LOPD. Van der Beek et al. \[25\] developed a Pompe-specific scale, i.e. the Rasch-built Pompe-specific activity (R-PAct) scale. Difficulty of tasks incorporated in different questionnaires differs substantially between neuromuscular diseases; this could be one reason why we do not find a significant change in the ActivLim score in LOPD. In Lachmann and Schoser \[26\], the minimally clinical important difference deterioration in FVC in non-treated Pompe patients would possibly be felt after 2 years, for the 6MWD this would be 9 years. This might also be an explanation why there is a change in some outcome measures, but not in the ActivLim score.

Not all changes in outcome measurements in neuromuscular diseases result in a change in functionality \[26\], the relation between motor function and activity level is not necessarily straightforward \[27, 28\]. Declines in walking distance, speed or forced vital capacity are not necessarily clinically significant or even perceived as a decline by the patient. Therefore, activity limitations should be assessed separately in patients with neuromuscular diseases, but in LOPD patients the ActivLim score may not be the best patient reported outcome measure to assess this.

When comparing mean values of respiratory function and 6MWD, findings in our LOPD cohort are comparable to earlier described LOPD patient groups \[10, 18, 29, 30\]. In the Austrian cohort, 6MWD during ERT was 373.5 m \[18\], and Kuperus et al. \[30\] showed that the median 6MWD changed from 376 to 416 m over a period of 5 years following ERT onset. They measured an increase in 6MWD during the first year after treatment onset, and a decline from then on. In the meta-analysis of Schoser et al. \[10\], where distances between 246 and 660 m were measured, the largest improvement of the 6MWD was measured the first 20 months after start of ERT. Similarly, in our cohort, the 6MWD declined over the years, but we collected data irrespective of ERT and of ERT duration.

The 6-min walk distance (6MWD) is most commonly used to measure exercise capacity in LOPD \[26, 31\]. This capacity may be limited by multiple causes, such as peripheral muscle weakness and respiratory function. Furthermore, this may vary between patients. In Duchenne and Becker muscular dystrophy, as well as in some pulmonary diseases, the 6MWD is a validated outcome measure, often used in combination with other tests, such as quantitative muscle MRI and Motor Function Measure \[26\]. Similarly to previous longitudinal cohorts in neuromuscular diseases \[32\], we showed that the 6MWD was a good outcome parameter in LOPD.

**Limitations and strengths of the study**

Because of the retrospective nature of the study, there were some missing data for different outcome measures, the patient population was heterogeneous concerning current age and disease duration since data were collected from a fixed timeframe (2010–2017), and there was no comparison with an untreated control group since most data in the study were obtained from treated LOPD patients.

Despite these shortcomings, we performed a detailed clinical, imaging and genetic characterisation of all Belgian LOPD patients and identified useful longitudinal outcome measures in LOPD that can be applied in future clinical trials.

**Conclusions**

Awareness on LOPD should even be further increased, as we found a long diagnostic delay as described in other populations. As ERT is more effective in the beginning of the disease, early start of therapy is important. In the follow-up of patients, physical outcome measures and patient reported outcome measures are needed, as the relation between these two is not straightforward. The 6MWD, but not the ActivLim score, is a sensitive outcome measure to follow up LOPD patients.

**Abbreviations**

10MWT: 10 m walk test; 6MWD: 6 min walking distance; CK: Serum creatine kinase; ERT: Enzyme replacement therapy; FVC: Forced vital capacity; GAA: Acid alpha-glucosidase; GSD2: Glycogen storage disease type 2; IOPD: Infantile onset Pompe disease; LOPD: Late onset Pompe disease; MRC: Medical Research Council; NIV: Non-invasive ventilation

**Acknowledgements**

Not applicable.

**Availability of data and study materials**

The supporting datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contribution**

All authors were involved in the data collection and critical revision of the article for the intellectual content and final approval of the version intended to be published. PV and KGC analysed and interpreted the patient data. SF performed statistical analyses.
Author information
GR has to disclose: financial support in order to attend several scientific meetings between 2008 and 2019 (Sanofi-Genezyme, CSL Behring, Santhera). Financial compensations for various consulting missions (Sanofi-Genezyme, CSL Behring, Santhera, AFM). Member of the INAMI/RIZIV commission for metabolic diseases (Pompe and Fabry). KGC and PVD are Chairholders of the Emil von Behring Chair for Neuromuscular and Neurodegenerative Disorders by CSL Behring. PVD holds a senior clinical investigatorship from FWO-Vlaanderen. KGC is member of the INAMI/RIZIV commission for metabolic diseases (Pompe).
Several authors of this publication are member of the European Reference Network for Rare Neurological Diseases (ERN EURO-NMDD) and of the European Reference Network for Rare Neurological Diseases (ERN RND).

Funding
The authors did not receive funding for this project.

Ethics approval and consent to participate
This retrospective study was approved by the Ethics Committee Research of University Hospitals Leuven / KU Leuven, Leuven, Belgium.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, Neuromuscular Reference Centre, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. 2KU Leuven – University of Leuven, Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium. 3Sciensano, Brussels, Belgium. 4Department of Radiology, University Hospitals Leuven, Leuven, Belgium. 5Department ofNeurology, Neuromuscular Reference Centre, University Hospital Gent, Gent, Belgium. 6Department ofNeurology, Neuromuscular Reference Centre, University Hospital Saint-Luc, Brussels, Belgium. 7Department ofNeurology, Neuromuscular Reference Centre, University Hospital Antwerpen, Antwerpen, Belgium. 8Department ofNeurology, Neuromuscular Reference Centre, University Hospital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 9Department ofNeurology, AZ Sint-Jan Brugge, Brugge, Belgium. 10Department ofNeurology, Neuromuscular Reference Centre of Liège, CHU Liège, Liège, Belgium. 11Department ofRehabilitation, Centre for Home Mechanical Ventilation and Neuromuscular Reference Centre, Rehabilitation Hospital Inkendaal, Brussels, Belgium. 12Department ofPulmonology, Leuven University Centre for Sleep and Wake Disorders, University Hospitals Leuven, Leuven, Belgium. 13VIB, Center for Brain & Disease Research, Laboratory ofNeurobiology, Leuven, Belgium. 14Department ofNeurosciences – Experimental Neurology, Laboratory for Muscle Diseases and Neuropathies, KU Leuven, Leuven, Belgium.

Received: 24 January 2020 Accepted: 17 March 2020
Published online: 05 April 2020

References
1. Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120(3):163–72.
2. Schoser B. Pompe disease: what are we missing? Ann Transl Med. 2019;7(13):1–7.
3. Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019;7(13):284.
4. Lamartine S, Monteiro M, Remiche G. Late-onset Pompe disease associated with polynuropathy. Neuromuscul Disord. 2019 Dec 29(12):968–72.
5. Remiche G, Herbaut A-G, Ronchi D, Lamperti C, Magri F, Moggs M, et al. Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition. Eur Neurol. 2012;68(2):75–8.
6. Hahn A, Schänzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7(3):1–10.
7. Stabbel. Key figures 2019. In: Looking at the facts [Internet]. 2019. [cited 2019 Dec 18]. Available from: https://statbelpr.belgium.be/en/news/key-figures-2019-looking-facts.
8. Erasmus MC. Pompe disease GAA variants database [internet]. 2019. Available from: http://www.pompevariante database.nl/pompe_mutations_list.php?orderby=a Mut_ID1.
9. van der Ploeg AT, Kruifshaar ME, Toscano A, Laforêt P, Angeli C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017 Jun 1;24(6):768–831.
10. Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following α-glucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621–30.
11. Vandervelde L, Van den Bergh PYK, Goemans N, Thonnard JL. ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord. 2007;17(6):459–69.
12. Vandervelde L, Van den Bergh PYK, Goemans N, Thonnard JL. Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionaire. Neuromuscul Disord. 2009;19(2):99–103.
13. Batcho CS, Van den Bergh PYK, Van Damme P, Roy AJ, Thonnard JL, Penta M. How robust is ACTIVLIM for the follow-up of activity limitations in patients with neuromuscular diseases? Neuromuscul Disord. 2016;26(3):211–20.
14. Rehab-scales; Université catholique de Louvain; Unité de Réadaptation et de Médecine Physique. Activlimg - Instructions [Internet]. 2007. Available from: http://rnsandbox.iescagilly.be/activlimg-instructions.html.
15. Reuser AJJ, van der Ploeg AT, Chien YH, Llenera J, Abbott MA, Clemens PR, et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe registry. Hum Mutat. 2019;40(11):2146–64.
16. Regression HF. Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, vol. XXIV. 1st ed. Verlag New York: Springer; 2001. p. 572.
17. Schoser B, Laforêt P, Kruifshaar ME, Toscano A, van Doorn PA, van der Ploeg AT, et al. 208th ENMC international workshop: formation of a European network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, the Netherlands, 26–28 September 2014. Neuromuscul Disord. 2015;25(8):674–8.
18. Lüscher WN, Huemer M, Stuligir T, Simschitz P, Iglisleder S, Eggers C, et al. Pompe disease in Austria: clinical, genetic and epidemiological aspects. J Neurol. 2018;265(1):159–64.
19. Zhao Y, Wang Z, Ju R, Xu H, Huang Y, Qiu Z, et al. Characteristics of Pompe disease in China: a report from the Pompe registry. Orphanet J Rare Dis. 2019;14(1):1–7.
20. Nazari F, Sinaei F, Nillpour Y, Fathei F, Streibel B, Ashrafi MR, et al. Late-onset Pompe disease in Iran: a clinical and genetic report. Muscle Nerve. 2017 Jun 155(6):835–40.
21. Montagnese F, Granata F, Musumeci O, Rodolico C, Mondello S, Barca E, et al. Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD). J Inherit Metab Dis. 2016;39(3):391–8.
22. Musumeci O, Marino S, Granata F, Morabito R, Bonanno L, Brizzi T, et al. Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis. Eur J Neurol. 2019;26(3):442–e35.
23. Leslie N, Bailey L. Pompe Disease [Internet]. In: Adam M, Ardinger H, Pagon R, editors. GeneReviews®. Seattle (WA): University of Washington. [cited 2020 Jan 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1261/.
24. Thompson BG, Brown RD, Amin-Hanjani S, Broderick JP, Cockroft KM, Connolly ES, et al. Guidelines for the Management of Patients with Unruptured Intracranial Aneurysms. Stroke. 2015 Aug 46(8):2368–400.
25. van der Beek NA, Hagemans ML, van der Ploeg AT, van Doorn PA, Merkies IS. The Rasch-built Pompe-specific activity (R-Pact) scale. Neuromuscul Disord. 2013;23(3):256–64.
26. Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis. 2013;8(1):160.
27. Vandervelde L, Van den Bergh PYK, Renders A, Goemans N, Thonnard JL. Relationships between motor impairments and activity limitations in patients with neuromuscular disorders. J Neurol Neurosurg Psychiatry. 2009;80(4):416–22.
28. Stepien KM, Hendekisz CJ, Roberts M, Sharma R. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over Syener. Mol Genet Metab. 2016;117(4):413–8.
29. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013;260(4):951–9.
30. Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, et al. Long-term benefit of enzyme replacement therapy in Pompe disease. Neurology. 2017;89(23):2365 LP–2373.

31. Crescimanno G, Modica R, Lo Mauro R, Musumeci O, Toscano A, Marrone O. Role of the cardio-pulmonary exercise test and six-minute walking test in the evaluation of exercise performance in patients with late-onset Pompe disease. Neuromuscul Disord. 2015;25(7):542–7.

32. Harlaar L, Hogrel J-Y, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouag N, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93(19):e1756–67.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.